News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inveresk Research (Incorporating CTBR) (IRGI) Announces First Quarter 2004 Earnings Release And Webcast


10/19/2005 5:10:44 PM

Conference Call on Wednesday, May 5, 2004 at 10:00 a.m. EDT

CARY, N.C--(BUSINESS WIRE)--April 7, 2004--Inveresk Research Group, Inc. (Nasdaq:IRGI - News) will be announcing its first quarter earnings results for the fiscal period ended March 31, 2004, after the market closes on Tuesday, May 4, 2004. Management of the company will host a conference call to discuss these results on Wednesday, May 5, 2004, at 10:00 a.m. Eastern Daylight Time. Presenting from the company will be Walter Nimmo, President and Chief Executive Officer and Paul Cowan, Chief Financial Officer.

The conference call will be webcast live and will also be available for replay two hours after the completion of the call until 5:00 p.m. EDT on Tuesday, May 11, 2004. The call is being webcast by CCBN and can be accessed at Inveresk's web site at www.inveresk.com

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).

Inveresk Research is a leading provider of drug development services to companies in the pharmaceutical and biotechnology industries. Through its pre-clinical and clinical business segments, the Company offers a broad range of drug development services, including pre-clinical safety and pharmacology evaluation services, laboratory sciences services and clinical development services. Inveresk Research is one of a small number of drug development services companies currently providing a comprehensive range of pre-clinical and clinical development services on a worldwide basis. The Company's client base includes major pharmaceutical companies in North America, Europe and Japan, as well as many biotechnology and specialty pharmaceutical companies. For more information on Inveresk Research, visit the Company's web site at http://www.inveresk.com.

Contact:

Financial Dynamics Matt Dallas, 212-850-5627 mdallas@fd-us.com

Source: Inveresk Research Group, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES